

Figure e-1. Discontinuations by extension study year (Safety population)






Figure e-2A. White blood cell and neutrophil counts over time, Core and Extension studies (Safety population)

i. White Blood Cells



No. of patients	0	24	48	72	96	120	144	168	192	216	240	264	288	312	336	360
14 mg/14 mg	250	243	243	242	236	209	221	213	205	188	182	174	151	114	97	71
Placebo/14 mg	105	103	102	102	102	93	95	84	78	75	76	76	59	44	34	29
7 mg/7 mg	254	245	247	248	235	220	231	211	202	181	184	174	136	106	87	59
Placebo/7 mg	130	127	126	128	127	117	111	104	97	92	90	83	66	43	39	33

ii. Neutrophils



No. of patients	0	24	48	72	96	120	144	168	192	216	240	264	288	312	336	360
14 mg/14 mg	250	243	243	242	236	209	220	213	205	188	181	174	151	114	97	71
Placebo/14 mg	105	103	102	101	102	93	95	84	78	75	76	76	59	44	34	29
7 mg/7 mg	254	245	246	247	235	220	231	211	202	181	184	174	136	106	87	59
Placebo/7 mg	130	127	126	128	127	117	111	104	97	92	90	83	66	43	39	33

Figure e-2B. Neutrophil counts over time, Core and Extension studies (Patients who discontinued treatment for Hematological Adverse Events)

